REVIEWERS COMMENTS. In vitro diagnosis of allergic sensitization is currently confirmed by using allergen extracts derived from natural source materials. The authors previously described creation of this recombinant major cat allergen, rFel d 1. Investigation with such purified recombinant proteins is a current area of intense interest within the field of allergy and immunology, because these e...

BACKGROUND Allergen-specific immunotherapy has been demonstrated to have potential for the treatment of allergic diseases. Transgenic animals are currently the best available bioreactors to produce recombinant proteins, which can be secreted in milk. It has not been clearly demonstrated whether milk from transgenic animals expressing recombinant allergens has immunomodulatory effects on allergi...

Currently, AIT represents the sole allergen-specific therapeutic approach dealing with IgE-mediated allergic disease able to control not only its symptoms, as other treatments do, but also to rebalance the immunological profile of allergic subjects. In fact, they develop detrimental immune responses towards allergens, exogenous proteins that should be otherwise harmless, entering the body from ...

Results The characterisation of CD23 via circular dichroism (CD) spectra and gel filtration showed folded, monomeric proteins. Binding of isolated monomeric human monoclonal IgE and of isolated polyclonal serum IgE as well as of both forms of IgE in complex with birch pollen allergen Bet v 1 to recombinant CD23 was demonstrated by ELISA and by surface plasmon resonance analysis. Next, we perfor...

In the past, the development of more effective, safe, convenient, broadly applicable, and easy to manufacture vaccines for allergen-specific immunotherapy (AIT) has been limited by the poor quality of natural allergen extracts. Progress made in the field of molecular allergen characterization has now made it possible to produce defined vaccines for AIT and eventually for preventive allergy vacc...

Recombinant allergens are a promising alternative to crude allergen extracts for diagnosis and therapy of allergic diseases. Genetically modified allergen derivatives with reduced allergenic activity but retaining their immunogenicity have also been produced to increase safety and specificity of allergen-specific immunotherapy. When a limited number of allergens are responsible for most of the ...

BACKGROUND Recombinant allergens are under investigation for replacing allergen extracts in immunotherapy. Site-directed mutagenesis has been suggested as a strategy to develop hypoallergenic molecules that will reduce the risk of side effects. For decades, chemically modified allergen extracts have been used for the same reason. AIM To evaluate whether glutaraldehyde modification is a good s...

BACKGROUND Buckwheat is a common food in Japan, Korea and other countries. A candidate major buckwheat allergen, a 16-kDa protein (BWp16), was previously characterized as a pepsin-resistant protein associated with immediate-type allergies to buckwheat. However, whether recombinant BWp16 can react with a patient's IgE remains uncertain. METHODS The cDNA encoding BWp16 from Japanese buckwheat s...

BACKGROUND The cultivation of saffron is expanding through the southeast of Iran, and allergy to saffron pollen occurs in workers involved in processing this plant. We aimed to clone, sequence and express a major allergen involved in saffron pollen allergy, and to compare the recombinant with the natural allergen. METHODS The N-terminal amino acid sequence of Cro s 1, an allergen from saffron...

BACKGROUND Mucosal vaccine based on lactic acid bacteria is an attractive concept for the prevention and treatment of allergic diseases, but their mechanisms of action in vivo are poorly understood. Therefore, we sought to investigate how recombinant major dust mite allergen Der p2-expressing Lactococcus lactis as a mucosal vaccine induced the immune tolerance against house dust mite allergy in...